DERIVATIVES OF COMPOUNDS CONTAINING PYRIDINE RINGS AS MALT1 INHIBITORS Russian patent published in 2024 - IPC C07D401/12 C07D401/14 C07D405/14 A61K31/444 A61P19/02 A61P29/00 A61P35/00 A61P37/02 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I) or its enantiomer, diastereomer or pharmaceutically acceptable salt form. In formula (I): R^x is C_1-4alkyl or C_3-6cycloalkyl; R^y is C_1-4alkyl; and R^z is hydrogen; R¹ is selected from a group consisting of hydrogen, -OR⁵, C_1-4alkyl, C_2-4alkenyl, halogen, -CN, C_3-6cycloalkyl, Het^a, -C(=O)-OH, -C(=O)-O-C_1-4alkyl, -NR^6aR^7a and -C(=O)-NR^6bR^7b; each of R^2a and R^2b is independently selected from a group consisting of hydrogen, -NR^6cR^7c, C_3-6cycloalkyl, C_1-4alkyl and C_1-4alkyl substituted with 1, 2 or 3 halogen atoms; X¹ is N or CR^a; X² is N or CR^b; provided that only one of X¹ and X² is N in any case; R³ is hydrogen, C_1-4alkyl or -OC_1-4alkyl; R⁴ is halogen, cyano or trifluoromethyl; R⁵ is selected from a group consisting of hydrogen, C_1-4alkyl, C_3-6cycloalkyl, Het^b and C_1-4alkyl substituted with one or two substituents, each independently selected from the group consisting of -C(=O)-NR⁸R⁹, -C(=O)-OH, -C(=O)-O-C_1-4alkyl, C_3-6cycloalkyl and phenyl; each of R^6a, R^6b, R^6c, R^7a, R^7b, R^7c, R⁸ and R⁹ is independently selected from the group consisting of hydrogen and C_1-4alkyl; Het^a is monocyclic 4–7-membered non-aromatic heterocyclyl containing one or two heteroatoms selected from nitrogen, oxygen and sulphur; Het^b is monocyclic 4–7-membered non-aromatic heterocyclyl containing one or two heteroatoms selected from nitrogen, oxygen and sulphur; R^a is -OC_1-4alkyl, each of which is optionally substituted with one, two or three substitutes representing a halogen atom; or R^a is 2H-1,2,3-triazol-2-yl or C_3-6cycloalkyl; wherein each of them is optionally substituted at one or two carbon atoms by means of a substituent, which in each case is independently selected from the group consisting of C_1-4 alkyl and C_1-4alkyl, substituted with one -OH; R^b is hydrogen. Also disclosed is a pharmaceutical composition containing a compound of formula (I), and a method of treating using the compound of formula (I).

EFFECT: disclosed compounds are inhibitors of MALT1 (mucosal lymphoid tissue translocation protein 1) and can be useful for treating a disease, syndrome, condition or disorder associated with MALT1 disease, syndrome, condition or disorder, including but not limited to cancer and immunological diseases.

9 cl, 5 tbl, 2 ex